{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T12:24:17Z","timestamp":1790425457382,"version":"4.1.0"},"reference-count":78,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2007,5,1]],"date-time":"2007-05-01T00:00:00Z","timestamp":1177977600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2007,5,1]],"date-time":"2007-05-01T00:00:00Z","timestamp":1177977600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transfusion Clinique et Biologique"],"published-print":{"date-parts":[[2007,5]]},"DOI":"10.1016\/j.tracli.2007.04.008","type":"journal-article","created":{"date-parts":[[2007,5,31]],"date-time":"2007-05-31T10:01:53Z","timestamp":1180605713000},"page":"51-62","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Manufacture of plasma-derived products in France and measures to prevent the risk of vCJD transmission: Precautionary measures and efficacy of manufacturing processes in prion removal"],"prefix":"10.1016","volume":"14","author":[{"given":"Beno\u00eet","family":"Flan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Arrabal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tracli.2007.04.008_bib1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1046\/j.1423-0410.2000.7810007.x","article-title":"Large-scale screening for human parvovirus B19 DNA by PCR: application to the quality control of plasma for fractionation","volume":"78","author":"Aubin","year":"2000","journal-title":"Vox Sang"},{"key":"10.1016\/j.tracli.2007.04.008_bib2","first-page":"S25","article-title":"Apport des techniques d\u2019amplification des acides nucl\u00e9iques viraux au contr\u00f4le de qualit\u00e9 du plasma pour fractionnement","volume":"9","author":"Flan","year":"2005","journal-title":"Virologie"},{"key":"10.1016\/j.tracli.2007.04.008_bib3","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1046\/j.1365-2516.2003.00701.x","article-title":"Nanofiltration of plasma-derived biopharmaceutical products","volume":"9","author":"Burnouf","year":"2003","journal-title":"Haemophilia"},{"key":"10.1016\/j.tracli.2007.04.008_bib4","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/S0140-6736(96)91412-9","article-title":"A new variant of Creutzfeldt Jakob disease in the UK","volume":"347","author":"Will","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.tracli.2007.04.008_bib5","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S0140-6736(94)91148-7","article-title":"Creutzfeldt-Jakob disease and blood transfusion","volume":"343","author":"Heye","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.tracli.2007.04.008_bib6","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1046\/j.1537-2995.1998.38998409000.x","article-title":"Surveillance for Creutzfeldt-Jakob disease among persons with hemophilia","volume":"38","author":"Evatt","year":"1998","journal-title":"Transfusion"},{"key":"10.1016\/j.tracli.2007.04.008_bib7","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/S0140-6736(98)24035-9","article-title":"Prion immunoreactivity in appendix before clinical onset of variant Creutzfeldt-Jakob disease","volume":"352","author":"Hilton","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.tracli.2007.04.008_bib8","unstructured":"Evaluation of the Risk of Transmission of New Variant Creutzfeldt-Jakob Disease by Blood and Blood Components: Recommendations. AFSSaPS. 11 December 2000."},{"key":"10.1016\/j.tracli.2007.04.008_bib9","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/S0140-6736(00)02719-7","article-title":"Transmission of BSE by blood transfusion in sheep","volume":"356","author":"Houston","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.tracli.2007.04.008_bib10","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S0140-6736(04)15486-X","article-title":"Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion","volume":"363","author":"Llewelyn","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.tracli.2007.04.008_bib11","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/j.1423-0410.2006.00833.x","article-title":"Creutzfeldt-Jakob disease and blood transfusion: results of the UK transfusion: medicine epidemiological review study","volume":"91","author":"Hewitt","year":"2006","journal-title":"Vox Sang"},{"key":"10.1016\/j.tracli.2007.04.008_bib12","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1016\/S0140-6736(06)69835-8","article-title":"Clinical presentation and pre-mortem diagnosis of variant Creutzfeldt-Jakob disease associated with blood transfusion: a case report","volume":"368","author":"Wroe","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.tracli.2007.04.008_bib13","unstructured":"HPA Press Statement, 18 January 2007, 4th case of variant CJD infection associated with blood transfusion."},{"key":"10.1016\/j.tracli.2007.04.008_bib14","unstructured":"Evaluation of the Risk of Transmission of New Variant Creutzfeldt-Jakob Disease by Blood and Blood Components. Update of findings of ad hoc group report of December 2000. Afssaps. Report of February 2004."},{"key":"10.1016\/j.tracli.2007.04.008_bib15","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.tracli.2006.11.001","article-title":"Current strategies to prevent transmission of prions by human plasma derivatives","volume":"13","author":"Burnouf","year":"2006","journal-title":"Transfus Clin Biol"},{"key":"10.1016\/j.tracli.2007.04.008_bib16","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1191\/0962280203sm337ra","article-title":"Extending backcalculation to analyse BSE data","volume":"12","author":"Donnelly","year":"2003","journal-title":"Stat Methods Med Res"},{"key":"10.1016\/j.tracli.2007.04.008_bib17","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1046\/j.1537-2995.1998.38998408999.x","article-title":"The distribution of infectivity in blood components and plasma derivatives in experimental models of transmissible spongiform encephalopathy","volume":"38","author":"Brown","year":"1998","journal-title":"Transfusion"},{"key":"10.1016\/j.tracli.2007.04.008_bib18","series-title":"WHO Guidelines on Tissue Infectivity Distribution in Transmissible Spongiform Encephalopathies","author":"Rohwer","year":"2006"},{"key":"10.1016\/j.tracli.2007.04.008_bib19","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S0140-6736(04)16812-8","article-title":"Effectiveness of leucoreduction for removal of infectivity of transmissible spongiform encephalopathies from blood","volume":"364","author":"Gregori","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.tracli.2007.04.008_bib20","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1016\/S0140-6736(06)69897-8","article-title":"Reduction in infectivity of endogenous transmissible spongiform encephalopathies present in blood by adsorption to selective affinity resins","volume":"368","author":"Gregori","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.tracli.2007.04.008_bib21","unstructured":"Evaluation of the Risk of Transmission of New Variant Creutzfeldt-Jakob Disease by Blood and Blood Components. Update of findings of ad hoc group report of December 2000. Afssaps. Report of February 2005."},{"key":"10.1016\/j.tracli.2007.04.008_bib22","unstructured":"Guideline on the investigation of manufacturing processes for plasma-derived medicinal products with regard to vCJD risk. EMEA\/CPMP\/BWP\/CPMP\/5136\/03, 21 October 2004."},{"key":"10.1016\/j.tracli.2007.04.008_bib23","unstructured":"CPMP position statement on Creutzfeldt-Jakob disease and plasma-derived and urine-derived medicinal products. EMEA\/CPMP\/BWP\/2879\/02. rev 1, 23 June 2004."},{"key":"10.1016\/j.tracli.2007.04.008_bib24","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1055\/s-0037-1615389","article-title":"A cross-over pharmacokinetic study of a double viral inactivated factor IX concentrate (15nm filtration and SD) compared to a SD factor IX concentrate","volume":"80","author":"Goudemand","year":"1998","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.tracli.2007.04.008_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1538-7836.2005.01435.x","article-title":"Pharmacokinetic studies on Wilfactin\u00ae, a von Willebrand factor concentrate with a low factor VIII content treated with three virus inactivation\/removal methods","volume":"3","author":"Goudemand","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.tracli.2007.04.008_bib26","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1046\/j.1537-2995.2003.t01-1-00351.x","article-title":"Variant CJD transmission through blood: risks to predictors and \u201cpredictees\u201d","volume":"43","author":"Brown","year":"2003","journal-title":"Transfusion"},{"key":"10.1016\/j.tracli.2007.04.008_bib27","unstructured":"Perron H. Immunoassay for the detection of resistant Prion protein (PrP-res) in human plasma using an original combination of chemical ligands. IBC TSE Conferences, June 2006, Vienna Austria."},{"key":"10.1016\/j.tracli.2007.04.008_bib28","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1016\/j.peptides.2005.03.006","article-title":"Rapid presymptomatic detection of PrPSc via conformationally responsive palindromic PrP peptides","volume":"11","author":"Grosset","year":"2005","journal-title":"Peptides"},{"key":"10.1016\/j.tracli.2007.04.008_bib29","series-title":"Guidelines ont Tissue Infectivity Distribution in Transmissible Spongiform Encephalopathies PN WHO press","year":"2006"},{"key":"10.1016\/j.tracli.2007.04.008_bib30","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1093\/ije\/dyh374","article-title":"Risk of variant Creutzfeldt-Jakob disease in France","volume":"34","author":"Chadeau-Hyam","year":"2005","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.tracli.2007.04.008_bib31","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/385197a0","article-title":"Predicting the CJD epidemic in humans","volume":"385","author":"Cousens","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.tracli.2007.04.008_bib32","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/35020688","article-title":"Predicted vCJD mortality in Great Britain","volume":"406","author":"Ghani","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.tracli.2007.04.008_bib33","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1002\/path.1580","article-title":"Prevalence of lymphoreticular prion protein accumulation in UK tissue samples","volume":"203","author":"Hilton","year":"2004","journal-title":"J Pathol"},{"key":"10.1016\/j.tracli.2007.04.008_bib34","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1136\/bmj.38804.511644.55","article-title":"Variant Creutzfeldt-Jakob disease: prion protein genotype analysis of positive appendix tissue samples from a retrospective prevalence study","volume":"332","author":"Ironside","year":"2006","journal-title":"BMJ"},{"key":"10.1016\/j.tracli.2007.04.008_bib35","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0140-6736(04)16811-6","article-title":"Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient","volume":"364","author":"Peden","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.tracli.2007.04.008_bib36","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1046\/j.1365-2516.2002.00617.x","article-title":"Factor VIII and transmissible spongiform encephalopathy: the case for safety","volume":"8","author":"Cervenakova","year":"2002","journal-title":"Haemophilia"},{"key":"10.1016\/j.tracli.2007.04.008_bib37","unstructured":"Baron H. EMEA Expert Workshop on human TSEs and plasma-derived medicinal products. 2000 London, England."},{"key":"10.1016\/j.tracli.2007.04.008_bib38","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/S0140-6736(01)05411-3","article-title":"Detection of variant Creutzfeldt-Jakob disease infectivity in extraneural tissues","volume":"358","author":"Bruce","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.tracli.2007.04.008_bib39","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0140-6736(01)05403-4","article-title":"Tissue distribution of protease resistant prion protein in variant Creutzfeldt-Jakob disease using a highly sensitive immunoblotting assay","volume":"358","author":"Wadsworth","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.tracli.2007.04.008_bib40","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1046\/j.1537-2995.1999.39111169.x","article-title":"Further studies of blood infectivity in an experimental model of transmissible spongiform encephalopathy, with an explanation of why blood components do not transmit Creutzfeldt-Jakob disease in humans","volume":"39","author":"Brown","year":"1999","journal-title":"Transfusion"},{"key":"10.1016\/j.tracli.2007.04.008_bib41","doi-asserted-by":"crossref","first-page":"4649","DOI":"10.1128\/JVI.76.9.4649-4650.2002","article-title":"Scrapie infectivity in hamster blood is not associated with platelets","volume":"76","author":"Holada","year":"2002","journal-title":"J Virol"},{"key":"10.1016\/j.tracli.2007.04.008_bib42","unstructured":"Rohwer in Reichl H. TSE's: safety of plasma derived products and lessons learned from spiking experiments. CHI's TSE meeting. February 2004."},{"key":"10.1016\/j.tracli.2007.04.008_bib43","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1053\/jhin.2000.0790","article-title":"Infectivity in the blood of mice with a BSE-derived agent","volume":"46","author":"Taylor","year":"2000","journal-title":"J Hosp Infect"},{"key":"10.1016\/j.tracli.2007.04.008_bib44","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1046\/j.0041-1132.2003.00586.x","article-title":"Similar levels of infectivity in the blood of mice infected with human-derived vCJD and GSS strains of transmissible spongiform encephalopathy","volume":"43","author":"Cervenakova","year":"2003","journal-title":"Transfusion"},{"key":"10.1016\/j.tracli.2007.04.008_bib45","unstructured":"Mc Cutcheon S, Hunter N, Foster JD, MacGregor I, Hornsey V, Prowse C, et al. Transmission of BSE infection, in sheep via blood transfusion. Prion 2006: strategies, advances and trends towards protection of society; October 2006, Torino Italy."},{"key":"10.1016\/j.tracli.2007.04.008_bib46","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1002\/ana.410350504","article-title":"Human spongiform encephalopathy: the National Institutes of Health series of 300 cases of experimentally transmitted disease","volume":"35","author":"Brown","year":"1994","journal-title":"Ann Neurol"},{"key":"10.1016\/j.tracli.2007.04.008_bib47","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1046\/j.1537-2995.2002.00098.x","article-title":"Brain and buffy coat transmission of bovine spongiform encephalopathy to the primate Microcebus murinus","volume":"42","author":"Bons","year":"2002","journal-title":"Transfusion"},{"key":"10.1016\/j.tracli.2007.04.008_bib48","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/S0140-6736(04)15487-1","article-title":"Tissue distribution of bovine spongiform encephalopathy agent in primates after intravenous or oral infection","volume":"363","author":"Herzog","year":"2004","journal-title":"Lancet"},{"issue":"Pt 11","key":"10.1016\/j.tracli.2007.04.008_bib49","doi-asserted-by":"crossref","first-page":"2897","DOI":"10.1099\/0022-1317-83-11-2897","article-title":"Transmission of prion diseases by blood transfusion","volume":"83","author":"Hunter","year":"2002","journal-title":"J Gen Virol"},{"key":"10.1016\/j.tracli.2007.04.008_bib50","unstructured":"Brandel JP. vCJD Epidemiology France. 3rd IPFA International scientific workshop on TSEs and the safety of blood components and plasma derivatives Paris 2006."},{"key":"10.1016\/j.tracli.2007.04.008_bib51","doi-asserted-by":"crossref","first-page":"79","DOI":"10.2165\/00063030-200519020-00002","article-title":"Ensuring the biological safety of plasma-derived therapeutic proteins: detection, inactivation, and removal of pathogens","volume":"19","author":"Cai","year":"2005","journal-title":"Biodrugs"},{"key":"10.1016\/j.tracli.2007.04.008_bib52","first-page":"144","article-title":"Contribution des \u00e9tapes de chromatographie \u00e0 l\u2019\u00e9limination des agents transmissibles non conventionnels dans la fabrication des m\u00e9dicaments d\u00e9riv\u00e9s du sang","volume":"13","author":"Arrabal","year":"2007","journal-title":"H\u00e9matologie"},{"key":"10.1016\/j.tracli.2007.04.008_bib53","first-page":"S45","article-title":"\u00c9valuation de l\u2019efficacit\u00e9 des proc\u00e9d\u00e9s de purification des proteins plasmatiques \u00e0 \u00e9liminer les agents transmissibles non conventionnels","volume":"9","author":"Flan","year":"2005","journal-title":"Virologie"},{"key":"10.1016\/j.tracli.2007.04.008_bib54","series-title":"Creutzfeldt-Jacob Disease: Managing the Risk of Transmission by Blood, Plasma and Tissues","first-page":"187","article-title":"Plasma products","author":"Foster","year":"2006"},{"key":"10.1016\/j.tracli.2007.04.008_bib55","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1046\/j.1537-2995.2001.41040449.x","article-title":"A direct relationship between partioning of the pathogenic prion protein and Transmissible Spongiform Encephalopathiy infectivity during the purification of plasma proteins","volume":"41","author":"Lee","year":"2001","journal-title":"Transfusion"},{"key":"10.1016\/j.tracli.2007.04.008_bib56","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1046\/j.1423-0410.2000.7820086.x","article-title":"Studies on the removal of abnormal prion protein by processes used in the manufacture of human plasma products","volume":"78","author":"Foster","year":"2000","journal-title":"Vox Sang"},{"key":"10.1016\/j.tracli.2007.04.008_bib57","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1006\/biol.2002.0327","article-title":"Purity of spiking agent affects partitioning of prions in plasma protein purification","volume":"30","author":"Vey","year":"2002","journal-title":"Biologicals"},{"key":"10.1016\/j.tracli.2007.04.008_bib58","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1046\/j.1423-0410.2002.00211.x","article-title":"Studies on the removal of bovine spongiform encephalopathy-derived agent by processes used in the manufacture of human immunoglobulin","volume":"83","author":"Reichl","year":"2002","journal-title":"Vox Sang"},{"key":"10.1016\/j.tracli.2007.04.008_bib59","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1046\/j.1423-0410.2003.00279.x","article-title":"Evaluation of virus and prion reduction in a new intravenous immunoglobulin manufacturing process","volume":"84","author":"Trejo","year":"2003","journal-title":"Vox Sang"},{"key":"10.1016\/j.tracli.2007.04.008_bib60","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.biologicals.2003.08.004","article-title":"Partitioning of TSE infectivity during ethanol fractionation of human plasma","volume":"32","author":"Gregori","year":"2004","journal-title":"Biologicals"},{"key":"10.1016\/j.tracli.2007.04.008_bib61","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/j.0042-9007.2004.00403.x","article-title":"Distribution of a bovine spongiform encephalopathy-derived agent over ion-exchange chromatography used in the preparation of concentrates of fibrinogen and factor VIII","volume":"86","author":"Foster","year":"2004","journal-title":"Vox Sang"},{"key":"10.1016\/j.tracli.2007.04.008_bib62","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/j.1423-0410.2006.00829.x","article-title":"Prion-removal capacity of chromatographic and ethanol precipitation steps used in the production of albumin and immunoglobulins","volume":"91","author":"Thyer","year":"2006","journal-title":"Vox Sang"},{"key":"10.1016\/j.tracli.2007.04.008_bib63","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1111\/j.1537-2995.2006.00864.x","article-title":"Removal of small nonenvelopped viruses by antibody-enhanced nanofiltration during the manufacture of plasma derivatives","volume":"46","author":"Kreil","year":"2006","journal-title":"Transfusion"},{"key":"10.1016\/j.tracli.2007.04.008_bib64","doi-asserted-by":"crossref","first-page":"357","DOI":"10.5360\/membrane.18.357","article-title":"Removal of causative agent of Creutzfeldt-Jakob Disease (CJD) through membrane filtration method","volume":"18","author":"Tateishi","year":"1993","journal-title":"Membrane"},{"key":"10.1016\/j.tracli.2007.04.008_bib65","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1006\/biol.2001.0269","article-title":"Scrapie removal using Planova virus removal filters","volume":"29","author":"Tateishi","year":"2001","journal-title":"Biologicals"},{"key":"10.1016\/j.tracli.2007.04.008_bib66","unstructured":"Losikoff A. Retention of TSE infectivity by Planova nanofilters as fonction of spike composition. IBC USA Conference Prions: Assessment and management of Risks from Blood-Borne TSE Infectivity. IBC USA Conference. April 2001."},{"key":"10.1016\/j.tracli.2007.04.008_bib67","unstructured":"Aranha M. FDA\/PDA Viral Clearance forum. October2001."},{"key":"10.1016\/j.tracli.2007.04.008_bib68","first-page":"58","article-title":"Potential prion risks and clearance by filtration","volume":"21","author":"Aranha","year":"2001","journal-title":"Genetic Engeneering News"},{"key":"10.1016\/j.tracli.2007.04.008_bib69","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.biologicals.2005.11.007","article-title":"CJD PrPsc removal by nanofiltration process: application to a therapeutic immunoglobulin solution (Lymphoglobuline)","volume":"34","author":"Truchot","year":"2006","journal-title":"Biologicals"},{"key":"10.1016\/j.tracli.2007.04.008_bib70","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1046\/j.1537-2995.2002.00160.x","article-title":"Removal of prion challenge from an immune globulin preparation by use of a size-exclusion filter","volume":"42","author":"Van Holten","year":"2002","journal-title":"Transfusion"},{"issue":"12 Sup2","key":"10.1016\/j.tracli.2007.04.008_bib71","first-page":"02PO33","article-title":"Efficient prion removal by 15nm nanofiltration after solvent-detergent treatment and ion-exchange chromatography in the manufacture of a nanofiltered factor VIII","author":"Porte","year":"2006","journal-title":"Haemophilia"},{"key":"10.1016\/j.tracli.2007.04.008_bib72","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/nature03989","article-title":"The most infectious prion protein particles","volume":"437","author":"Silveira","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.tracli.2007.04.008_bib73","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1111\/j.1537-2995.2005.00640.x","article-title":"Removal of exogenous (spiked) and endogenous prion infectivity from red cells with a new prototype of leukoreduction filter","volume":"45","author":"Sowemimo-Coker","year":"2005","journal-title":"Transfusion"},{"key":"10.1016\/j.tracli.2007.04.008_bib74","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1111\/j.1537-2995.2006.00763.x","article-title":"Preparation of soluble infectious samples from scrapie-infected brain: a new tool to study the clearance of transmissible spongiform encephalopathy agents during plasma fractionation","volume":"46","author":"Berardi","year":"2006","journal-title":"Transfusion"},{"key":"10.1016\/j.tracli.2007.04.008_bib75","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1126\/science.1128635","article-title":"Prion-induced amyloid heart disease with high blood infectivity in transgenic mice","volume":"313","author":"Trifilo","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.tracli.2007.04.008_bib76","doi-asserted-by":"crossref","first-page":"11312","DOI":"10.1073\/pnas.0604021103","article-title":"Human prions and plasma lipoproteins","volume":"103","author":"Safar","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.tracli.2007.04.008_bib77","doi-asserted-by":"crossref","unstructured":"Unal A, Thyer J, Uren E, Middleton D, Braun M, Maher D. Investigation by bioassay of the efficacy of sodium hydroxide treatment on the inactivation of mouse-adapted scrapie. Biologicals 2007, in press, doi:10.1016\/j.biologicals.2006.08.003.","DOI":"10.1016\/j.biologicals.2006.08.003"},{"issue":"12 Sup2","key":"10.1016\/j.tracli.2007.04.008_bib78","first-page":"02PO34","article-title":"Development of an in vitro TSE infectivity assay and application to validation of manufacturing processes","author":"You","year":"2006","journal-title":"Haemophilia"}],"container-title":["Transfusion Clinique et Biologique"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S124678200700078X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S124678200700078X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T10:29:52Z","timestamp":1761128992000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S124678200700078X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,5]]},"references-count":78,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,5]]}},"alternative-id":["S124678200700078X"],"URL":"https:\/\/doi.org\/10.1016\/j.tracli.2007.04.008","relation":{},"ISSN":["1246-7820"],"issn-type":[{"value":"1246-7820","type":"print"}],"subject":[],"published":{"date-parts":[[2007,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Manufacture of plasma-derived products in France and measures to prevent the risk of vCJD transmission: Precautionary measures and efficacy of manufacturing processes in prion removal","name":"articletitle","label":"Article Title"},{"value":"Transfusion Clinique et Biologique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tracli.2007.04.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2007 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}